Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543465 | 0.96 | HSD11B1 (0.32) | HSD11B1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1202719 | 0.96 | KDM4E (0.32) | HSD11B1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1203653 | 0.95 | KDM4E (0.32) | HSD11B1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL4102107 | 0.85 | MARK3 (0.32) | HSD11B1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1675579 | 0.85 | KMT2A (0.33) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL2298460 | 0.84 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL1675820 | 0.84 | KMT2A (0.32) | HSD11B1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1559101 | 0.83 | PLK1 (0.33) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL1203370 | 0.83 | KDM4E (0.32) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL1675845 | 0.82 | KMT2A (0.32) | KDM4EMEN1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | HSD11B1 83/4885KDM4E 3977/4885MEN1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.